RADIANCE
Financiado
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to prec...
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials
More than 50% of cancer patients undergo radiation therapy (RT) in the course of their treatment. However, because of a lack of specificity for tumor tissues, delivering therapeutically effective doses of X rays with tolerable tox...
More than 50% of cancer patients undergo radiation therapy (RT) in the course of their treatment. However, because of a lack of specificity for tumor tissues, delivering therapeutically effective doses of X rays with tolerable toxicity on healthy tissues remains a challenge. Glioblastoma multiforme (GBM), the most common primary brain cancer in adults has a dismal prognosis despite an aggressive standard-of-care. Developing new strategies to improve the therapeutic index of RT is therefore of major importance. The aim of this project is to comprehensively study the multifaceted radiotherapeutic effect of nanoscintillators (NS), and determine how to harness these effects to improve the therapeutic index of RT. By converting high-energy photons such as X-rays into UV/visible photons, NS can augment RT by various effects. These include radiation dose enhancement, radioluminescence-induced photodynamic therapy and DNA damage generated by UV-radioluminescence. This project has three main objectives: 1) To elucidate the physical and photochemical origins of the radiotherapeutic effects of NS using spectroscopic studies to identify the reactive oxygen species and DNA lesions generated upon X-rays; 2) To study the biological impact of the NS on 3D models and in syngeneic rat models of GBM; 3) To develop an in silico program that simulates the efficacy of prospective NS, and studies the impact of their composition, size and morphology. This will tailor future NS to specific malignancies with distinct biological properties. With this innovative methodology and an interdisciplinary approach that ranges from physics to biology, this project will provide ground-breaking fundamental knowledge on the radiotherapeutic effects of NS that may lead to highly valuable and clinically translatable therapies. In the long-term, this strategy may be tailored for pancreatic and metastatic ovarian cancers, for which the multifaceted enhancement of RT efficacy by NS may be of great interest.
ver más
Duración del proyecto: 63 meses
Fecha Inicio: 2023-09-12
Fecha Fin: 2028-12-31
Fecha Fin: 2028-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-12
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG:
ERC STARTING GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5